Works matching DE "APATINIB"

Results: 273

Neoadjuvant camrelizumab plus chemotherapy or apatinib for resectable stage IIA–IIIA NSCLC: a multicenter, two-arm, phase II exploratory trial.

Published in:

BMC Medicine, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12916-025-04250-4

By:

Ji, Shuyu;
Sheng, Zhenxin;
Bian, Dongliang;
Bao, Minwei;
Jin, Kaiqi;
Zhang, Wentian;
Zhu, Xinsheng;
Sun, Fenghuan;
Xia, Haoran;
Zhang, Han;
Shen, Ziyun;
Yu, Huansha;
Zhang, Lele;
Huang, Jie;
Peng, Zhang;
Song, Nan;
Wang, Haifeng;
Qian, Biyun;
Zhu, Yuming

Publication type:

Article

Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02).

Published in:

Frontiers in Oncology, 2025, p. 1, doi. 10.3389/fonc.2025.1615911

By:

Yuan, Hang;
Li, Zhen;
Cao, Guang-Shao;
Xu, Fei;
Wu, Gang;
Ding, Peng-Xu;
Wei, Qiu-Liang;
Chang, Zu-Kuan;
Xing, Cheng;
Niu, Huan-Zhang;
Yin, Jun;
Yao, Quan-Jun;
Zheng, Lin;
Xiao, Jin-Cheng;
Chen, Cheng-Shi;
Cheng, Hong-Tao;
Zong, Deng-Wei;
Xia, Wei-Li;
Geng, Xiang;
Zhao, Xiao-Hui

Publication type:

Article

Cholesterol confers resistance to Apatinib-mediated ferroptosis in gastric cancer.

Published in:

Cell & Bioscience, 2025, v. 15, n. 1, p. 1, doi. 10.1186/s13578-025-01435-5

By:

Li, Zhiwei;
Liu, Chenxin;
Wang, Minghao;
Wei, Riqing;
Li, Ru;
Huang, Kaihua;
Liang, Huayuan;
Li, Guoxin;
Zhao, Liying

Publication type:

Article

Case Report: Durable complete response of advanced-stage hepatocellular carcinoma to DEB−TACE combined with lenvatinib and camrelizumab.

Published in:

Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1549675

By:

Xu, Baiguo;
Cui, Yufeng;
Wang, Ning;
Gao, Zhongsong;
Ye, Qing;
Xiang, Huiling

Publication type:

Article

Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study.

Published in:

European Radiology, 2023, v. 33, n. 12, p. 8669, doi. 10.1007/s00330-023-09754-2

By:

Jin, Zhi-Cheng;
Zhong, Bin-Yan;
Chen, Jian-Jian;
Zhu, Hai-Dong;
Sun, Jun-Hui;
Yin, Guo-Wen;
Ge, Nai-Jian;
Luo, Biao;
Ding, Wen-Bin;
Li, Wen-Hui;
Chen, Li;
Wang, Yu-Qing;
Zhu, Xiao-Li;
Yang, Wei-Zhu;
Li, Hai-Liang;
Teng, Gao-Jun

Publication type:

Article

Long-term survival in a patient with ruptured advanced hepatocellular carcinoma treated with nutritional therapy combined with apatinib and camrelizumab: a case report.

Published in:

Discover Oncology, 2025, v. 16, n. 1, p. 1, doi. 10.1007/s12672-025-02099-w

By:

Liang, Yaohao;
Ruan, Tianyu;
He, Jiaqian;
Huang, Ketuan;
Wei, Min;
Tan, Shengqiang

Publication type:

Article

Use of Apatinib as a Bait to Fish its Unexpected Kinase Targets from the Hepatocellular Carcinoma Druggable Kinome.

Published in:

Journal of Computational Biophysics & Chemistry, 2023, v. 22, n. 4, p. 439, doi. 10.1142/S2737416523500187

By:

Liu, Rui;
Liu, Lijun

Publication type:

Article

The Role of Angiogenesis Targeted Therapies in Metastatic Advanced Gastric Cancer: A Narrative Review.

Published in:

Journal of Clinical Medicine, 2023, v. 12, n. 9, p. 3226, doi. 10.3390/jcm12093226

By:

Nakayama, Izuma;
Takahari, Daisuke

Publication type:

Article

Editorial: Apatinib and Anlotinib in the Treatment of Radioactive Iodine Refractory and Highly Invasive Thyroid Carcinoma.

Published in:

Journal of Clinical Medicine, 2022, v. 11, n. 21, p. 6380, doi. 10.3390/jcm11216380

By:

Jia, Wenqing;
Liu, Zhuoran;
Zhan, Ling;
Zhao, Qiwu;
Qiu, Weihua;
Kuang, Jie

Publication type:

Article

A gelable polymer loaded with curcumin and apatinib absorbed in gelatin sponge delays postoperative residual tumor growth.

Published in:

Scientific Reports, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41598-025-97732-7

By:

Meng, Zhuo-Nan;
Chen, Jian-Yuan;
Yu, Chong;
Zheng, Ai-hong;
Reddy, O. Sreekanth;
Liu, Kai-Yan;
Su, Yong-Rui;
Zhang, Shi-Tai;
Wang, Yin-Shuang;
Gu, Hang-Yu;
Wang, Fu-Wei;
Xu, Song-Cheng;
Sun, Li-Tao;
Chen, Bing-Chen;
Lai, Wing-Fu;
Wu, Guo-Qing;
Zhang, Da-Hong

Publication type:

Article

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study.

Published in:

Frontiers in Immunology, 2024, p. 1, doi. 10.3389/fimmu.2023.1298418

By:

Yunyan Mo;
Yufei Pan;
Bin Zhang;
Jian Zhang;
Yixin Su;
Zhengchun Liu;
Meiqing Luo;
Guanjie Qin;
Xiangyun Kong;
Rongjun Zhang;
Yu Pan;
Yi Liang;
Defeng Wang;
Yuejia Wei;
Hengwei Chen;
Wei Jiang

Publication type:

Article

Antitumor activity and safety of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma: An open-label, multicenter, phase II study.

Published in:

Frontiers in Immunology, 2023, v. 14, p. 01, doi. 10.3389/fimmu.2023.1128172

By:

Yanfei Liu;
Yuqin Song;
Shubo Zuo;
Xian Zhang;
Hui Liu;
Jingwen Wang;
Jingbo Wang;
Yongjing Tang;
Wen Zheng;
Zhitao Ying;
Lingyan Ping;
Chen Zhang;
Meng Wu;
Jun Zhu;
Yan Xie

Publication type:

Article

Efficacy and safety of tyrosine kinase inhibitors in treating refractory thyroid cancer: A network meta-analysis.

Published in:

Journal of Chinese Pharmaceutical Sciences, 2025, v. 34, n. 5, p. 470, doi. 10.5246/jcps.2025.05.036

By:

Yixiao Zhu;
Lirong Zhang;
Wenhua Wu;
Huiting Lin;
Xiaoxia Wei

Publication type:

Article

Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors.

Published in:

Cancer Research & Treatment, 2024, v. 56, n. 3, p. 743, doi. 10.4143/crt.2023.980

By:

Yoon-Koo Kang;
Min-Hee Ryu;
Yong Sang Hong;
Chang-Min Choi;
Tae Won Kim;
Baek-Yeol Ryoo;
Jeong Eun Kim;
Weis, John R.;
Kingsford, Rachel;
Cheol Hee Park;
Seong Jang;
McGinn, Arlo;
Werner, Theresa L.;
Sharma, Sunil

Publication type:

Article

Apatinib induces endoplasmic reticulum stress-mediated apoptosis and autophagy and potentiates cell sensitivity to paclitaxel via the IRE-1α–AKT–mTOR pathway in esophageal squamous cell carcinoma.

Published in:

Cell & Bioscience, 2021, v. 11, n. 1, p. 1, doi. 10.1186/s13578-021-00640-2

By:

Wang, Yu-Ming;
Xu, Xin;
Tang, Jian;
Sun, Zhi-Yong;
Fu, Yu-Jie;
Zhao, Xiao-Jing;
Ma, Xiu-Mei;
Ye, Qing

Publication type:

Article

Retracted: Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma.

Published in:

2024

By:

International, Emergency Medicine

Publication type:

Correction Notice

Clinical Effect of Apatinib Mesylate Tablets Combined with Paclitaxel Concurrent Radiotherapy and Chemotherapy in the First-Line Treatment of Locally Advanced Nasopharyngeal Carcinoma.

Published in:

Emergency Medicine International, 2022, p. 1, doi. 10.1155/2022/6293816

By:

Zhan, Dechao;
Chen, Zihong;
Yang, Donghong;
Wen, Jiyu;
Liu, Wanwan

Publication type:

Article

Apatinib sensitizes chemoresistant NSCLC cells to doxetaxel via regulating autophagy and enhances the therapeutic efficacy in advanced and refractory/recurrent NSCLC.

Published in:

Molecular Medicine Reports, 2020, v. 22, n. 5, p. 3935

By:

Hu, Rong;
Li, Tao;
Hui, Kaiyuan;
Chen, Zi;
Wang, Nan;
Wu, Xingping;
Ge, Linyang;
Zhou, Linfu

Publication type:

Article

The anti-tumor efficiency of low-dose apatinib-based chemotherapy in pretreated HER2-negative breast cancer with brain metastases.

Published in:

Annals of Medicine, 2023, v. 55, n. 1, p. 1, doi. 10.1080/07853890.2023.2218647

By:

Chen, Xuelian;
Bai, Xue;
Xie, Xiaofeng;
Huang, Jiayi;
Chen, Liping;
Song, Lin;
Lan, Xiaofeng;
Zhang, Qiuyi;
Guo, Jinfeng;
Du, Caiwen

Publication type:

Article

Camrelizumab plus apatinib in patients with advanced or recurrent endometrial cancer after failure of at least one prior systemic therapy (CAP 04): a single-arm phase II trial.

Published in:

BMC Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12916-024-03564-z

By:

Tian, Wenjuan;
Ren, Yulan;
Lu, Jing;
Jing, Chuyu;
Zhang, Wei;
Li, Haiming;
Wang, Tingting;
Hou, Zhiguo;
Yang, Ting;
Zhu, Wenqing;
Zhang, Yi;
Shan, Boer;
Yang, Huijuan;
Cheng, Xi;
Wang, Huaying

Publication type:

Article

A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas.

Published in:

BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-03132-x

By:

Zhou, Yan;
Li, Mei;
Zhang, Bing;
Yang, Cheng;
Wang, Yaling;
Zheng, Shuier;
Tang, Lina;
Zhou, Chenliang;
Qian, Guowei;
Huang, Yujing;
Yu, Wenxi;
Li, Hongtao;
Wang, Yonggang;
He, Aina;
Shen, Zan;
Zhang, Jianjun;
Li, Xiaoshuang;
Yang, Qingcheng;
Hu, Haiyan;
Yao, Yang

Publication type:

Article

A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.

Published in:

BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-03046-8

By:

Liu, Yaxin;
Wang, Wei;
Yin, Rutie;
Zhang, Youzhong;
Zhang, Yu;
Zhang, Keqiang;
Pan, Hongming;
Wang, Ke;
Lou, Ge;
Li, Guiling;
Zhang, Ruyan;
Li, Kun;
Rao, Jing;
Zhang, Ben;
Wang, Yuting;
Wang, Quanren;
Gao, Yunong;
Li, Huiping

Publication type:

Article

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study.

Published in:

BMC Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12916-023-02841-7

By:

Li, Jin;
Qin, Shukui;
Wen, Lu;
Wang, Junsheng;
Deng, Wenying;
Guo, Weijian;
Jia, Tongfu;
Jiang, Da;
Zhang, Guifang;
He, Yifu;
Ba, Yi;
Zhong, Haijun;
Wang, Lin;
Lin, Xiaoyan;
Yang, Jianwei;
Zhao, Jun;
Bai, Yuxian;
Wu, Xiangyuan;
Gao, Feng;
Sun, Guogui

Publication type:

Article

Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients.

Published in:

BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-14207-8

By:

Wu, Shusheng;
Luo, Huiqin;
Chen, Wenju;
Liu, Xudong;
Li, Huimin;
Li, Mengge;
Ke, Lihong;
Niu, Jiayu;
Hu, Bing;
Xu, Huijun;
Wang, Gang;
Yan, Ying;
Cao, Lulu;
Hu, Xiaoxiu;
Li, Chenghui;
He, Yifu

Publication type:

Article

Hepatic artery infusion chemotherapy combined with camrelizumab and apatinib as conversion therapy for patients with unresectable hepatocellular carcinoma: a single-arm exploratory trial.

Published in:

BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-14250-5

By:

Yalikun, Kugeluke;
Li, Zhongchao;
Zhang, Jianxin;
Chang, Zhibin;
Li, Mingming;
Sun, Zhicheng;
Liu, Zhaogang;
Yang, Yue;
Xu, Lei;
Li, Lei;
Zhang, Chengsheng;
Sun, Pengfei;
Zhong, Jingtao;
Cui, Kai;
Shi, Xuetao;
Zhang, Bo;
Zhao, Lei

Publication type:

Article

PD-1 inhibitors improve the efficacy of transcatheter arterial chemoembolization combined with apatinib in advanced hepatocellular carcinoma: a meta-analysis and trial sequential analysis.

Published in:

BMC Cancer, 2025, v. 25, n. 1, p. 1, doi. 10.1186/s12885-025-13932-4

By:

Yu, Jiahui;
Yu, Jinxin;
Chen, Yimiao;
Yang, Yuting;
Yi, Pengsheng

Publication type:

Article

Establishment and validation of a population pharmacokinetic model for apatinib in patients with tumors.

Published in:

BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-13118-4

By:

Zuo, Li'an;
Ling, Jing;
Hu, Nan;
Chen, Rong

Publication type:

Article

Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.

Published in:

Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 5, p. 411, doi. 10.1007/s00280-023-04563-2

By:

Ma, Yuxiang;
Chen, Qun;
Zhang, Yang;
Xue, Jinhui;
Liu, Qianwen;
Zhao, Yuanyuan;
Yang, Yunpeng;
Huang, Yan;
Fang, Wenfeng;
Hou, Zhiguo;
Li, Shaorong;
Wang, Jing;
Zhang, Li;
Zhao, Hongyun

Publication type:

Article

免疫检查点抑制剂联合抗血管生成二线治疗晚期食管癌患者疗效及肿瘤标志物表达、预后生存期的影响.

Published in:

Progress in Modern Biomedicine, 2023, v. 23, n. 22, p. 4375, doi. 10.13241/j.cnki.pmb.2023.22.035

By:

季从飞;
苏小琴;
倪婷婷;
于洋;
陈佳

Publication type:

Article

吡格列酮诱导心肌细胞凋亡和抑制心肌细胞肥大的作用及其机制研究.

Published in:

Progress in Modern Biomedicine, 2021, v. 21, n. 20, p. 3856, doi. 10.13241/j.cnki.pmb.2021.20.011

By:

陈红;
段多喜;
雷英;
高水群;
唐静;
吴茜

Publication type:

Article

替吉奥联合阿帕替尼对晚期复发转移食管癌患者T细胞亚群和血清肿瘤标志物水平的影响.

Published in:

Progress in Modern Biomedicine, 2021, v. 21, n. 15, p. 2958, doi. 10.13241/j.cnki.pmb.2021.15.033

By:

鲍健;
孙祥;
李红霞;
刘柳;
汪毅;
耿春花

Publication type:

Article

替吉奥联合阿帕替尼对晚期复发转移食管癌患者T细胞亚群和血清肿瘤标志物水平的影响.

Published in:

Progress in Modern Biomedicine, 2021, n. 13, p. 2958, doi. 10.13241/j.cnki.pmb.2021.15.033

By:

鲍健;
孙祥;
李红霞;
刘柳;
汪毅;
耿春花

Publication type:

Article

阿帕替尼对二线化疗失败晚期胃癌患者肿瘤标志物与胃黏膜四项水平及预后的影响.

Published in:

Progress in Modern Biomedicine, 2021, n. 13, p. 2583, doi. 10.13241/j.cnki.pmb.2021.13.039

By:

郑虹;
黄勇;
程莹星;
张丽娟;
姜孝娟

Publication type:

Article

伊立替康联合阿帕替尼治疗术后转移性胃癌患者临床疗效和安全性分析.

Published in:

Progress in Modern Biomedicine, 2021, n. 12, p. 2293, doi. 10.13241/j.cnki.pmb.2021.12.021

By:

李磊;
王韬;
曾俊琳;
王一飞;
费建东;
宋小涛;
胡振顺;
李倩

Publication type:

Article

阿帕替尼联合多西他赛对多线治疗晚期非小细胞肺癌患者血清肿瘤标志物、免疫功能及生活质量的影响.

Published in:

Progress in Modern Biomedicine, 2021, v. 21, n. 6, p. 1160, doi. 10.13241/j.cnki.pmb.2021.06.036

By:

丁婷婷;
芮晓艳;
范洪峰;
张艳喜;
陈军;
徐锐

Publication type:

Article

Clinical observation of apatinib-related hypothyroidism in patients with advanced malignancies.

Published in:

Experimental & Therapeutic Medicine, 2020, v. 20, n. 3, p. 1961

By:

Xiao, Junjuan;
Liang, Jing;
Zhang, Wei;
Li, Yan

Publication type:

Article

Effectiveness and prognostic factors of apatinib treatment in patients with recurrent or advanced cervical carcinoma: A retrospective study.

Published in:

Cancer Medicine, 2021, v. 10, n. 13, p. 4282, doi. 10.1002/cam4.3966

By:

Yang, Hui;
Chen, Min;
Mei, Zijie;
Xie, Conghua;
Zhou, Yunfeng;
Qiu, Hui

Publication type:

Article

Camptothecin enhances the anti-tumor effect of low-dose apatinib combined with PD-1 inhibitor on hepatocellular carcinoma.

Published in:

Scientific Reports, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41598-024-57874-6

By:

Wang, Hankang;
Gao, Congcong;
Li, Xiaodong;
Chen, Feng;
Li, Guijie

Publication type:

Article

Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma.

Published in:

Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.739139

By:

Cui, Lixuan;
Yan, Liang;
Guan, Xiaoya;
Dong, Bin;
Zhao, Min;
Lv, Ang;
Liu, Daoning;
Wang, Zhen;
Liu, Faqiang;
Wu, Jianhui;
Tian, Xiuyun;
Hao, Chunyi

Publication type:

Article

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer.

Published in:

Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-30569-0

By:

Liu, Jieqiong;
Wang, Ying;
Tian, Zhenluan;
Lin, Ying;
Li, Hengyu;
Zhu, Zhaowen;
Liu, Qiang;
Su, Shicheng;
Zeng, Yinduo;
Jia, Weijuan;
Yang, Yaping;
Xu, Shengqiang;
Yao, Herui;
Jiang, Wen;
Song, Erwei

Publication type:

Article

Transarterial Chemoembolization plus Apatinib with or without Camrelizumab for the Treatment of Advanced HBV-related Hepatocellular Carcinoma.

Published in:

Journal of Gastrointestinal & Liver Diseases, 2023, v. 32, n. 2, p. 182, doi. 10.15403/jgld-4667

By:

Haonan Liu;
Qianqian Yu;
Ting Gu;
Pengfei Qu;
Xiao Ma;
Shuang Zhou;
Tong Lu;
Di Pan;
Zhengxiang Han

Publication type:

Article

Comparing Safety and Efficacy of TACE + Apatinib in Combination with a PD-1 Inhibitor versus a Non-triple Therapy for Treating Advanced Primary Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.

Published in:

Journal of Gastrointestinal & Liver Diseases, 2023, v. 32, p. 85, doi. 10.15403/jgld-5159

By:

Di Pan;
Haonan Liu;
Pengfei Qu;
Xiaoxiao Chen;
Xiao Ma;
Yuqin Wang;
Xiaobing Qin;
Zhengxiang Han

Publication type:

Article

Prevalence and treatment of human epidermal growth factor receptor 2-altered non-small cell lung cancer: a retrospective analysis and systematic literature review.

Published in:

Ecancermedicalscience, 2024, v. 18, n. 1706-1753, p. 1, doi. 10.3332/ecancer.2024.1734

By:

Ning Yi Yap;
Perumal, Komathi;
Rajadurai, Pathmanathan

Publication type:

Article

Apatinib modulates sorafenib-resistant hepatocellular carcinoma through inhibiting the EGFR/JNK/ERK signaling pathway.

Published in:

Oncology Research, 2025, v. 33, n. 6, p. 1459, doi. 10.32604/or.2025.060407

By:

FAN, DEXUE;
SU, WEI;
BI, ZHAOWEN;
WANG, XINXING;
XU, XIANWEN;
MA, MINGZE;
ZHU, LICHAO;
ZHANG, ZHENHAI;
GAO, JUNLIN

Publication type:

Article

Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2.

Published in:

Xenobiotica, 2022, v. 52, n. 7, p. 669, doi. 10.1080/00498254.2022.2137068

By:

Kojima, Ayaka;
Nadai, Masayuki;
Murayama, Norie;
Yamazaki, Hiroshi;
Katoh, Miki

Publication type:

Article

Fasting mimicking diet inhibits tumor-associated macrophage survival and pro-tumor function in hypoxia: implications for combination therapy with anti-angiogenic agent.

Published in:

Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04577-7

By:

Wang, Lei;
Wang, Yu-jie;
Wang, Rong;
Gong, Fu-lian;
Shi, Yu-huan;
Li, Sheng-nan;
Chen, Pan-pan;
Yuan, Yong-fang

Publication type:

Article

Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.

Published in:

BMC Medicine, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12916-025-04159-y

By:

Kan, Xue-Feng;
Liang, Bin;
Zhang, Xiao-Lin;
Yu, Lei;
Luo, Yao-Chang;
Zhou, Shi;
Liu, Rui-Bao;
Xu, Guo-Hui;
Li, Hai-Liang;
Liao, Zheng-Yin;
Xiang, Hua;
Lu, Wei;
Xu, Lin-Feng;
Ma, Yi-Long;
Xia, Xiang-Wen;
Qian, Kun;
Dong, Xiang-Jun;
Xiong, Fu;
Song, Song-Lin;
Zhao, Chang

Publication type:

Article

Transarterial chemoembolization plus apatinib for unresectable hepatocellular carcinoma: a multicenter, randomized, open-label, phase III trial.

Published in:

BMC Medicine, 2025, v. 23, n. 1, p. 1, doi. 10.1186/s12916-025-04159-y

By:

Kan, Xue-Feng;
Liang, Bin;
Zhang, Xiao-Lin;
Yu, Lei;
Luo, Yao-Chang;
Zhou, Shi;
Liu, Rui-Bao;
Xu, Guo-Hui;
Li, Hai-Liang;
Liao, Zheng-Yin;
Xiang, Hua;
Lu, Wei;
Xu, Lin-Feng;
Ma, Yi-Long;
Xia, Xiang-Wen;
Qian, Kun;
Dong, Xiang-Jun;
Xiong, Fu;
Song, Song-Lin;
Zhao, Chang

Publication type:

Article

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial.

Published in:

BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10661-4

By:

Zhang, Le;
Wang, Weixue;
Ge, Shaohua;
Li, Hongli;
Bai, Ming;
Duan, Jingjing;
Yang, Yuchong;
Ning, Tao;
Liu, Rui;
Wang, Xia;
Ji, Zhi;
Wang, Feixue;
Zhang, Haiyang;
Ba, Yi;
Deng, Ting

Publication type:

Article

The efficacy of small molecule anti-angiogenic drugs in previously treated Thymic carcinoma.

Published in:

BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-022-10448-z

By:

Guan, Yelan;
Gu, Xiaodong;
Si, Jinfei;
Xiang, Jing;
Wei, Jingwen;
Hao, Yue;
Wang, Wenxian;
Sun, Yan

Publication type:

Article